Studies Show Effective Treatment – So Why Are Nursing Home Patients Being Left To Die with COVID-19 Untreated?

Studies Show Effective Treatment – So Why Are Nursing Home Patients Being Left To Die with COVID-19 Untreated?

James Lyons-Weiler, PhD 5/17/2020

“Our loved ones need not die so Fauci and Gates can have his moment in the sun with a vaccine next year.”

THE STUDIES OUT OF CHINA were clear: hydroxychloroquine improved health outcomes of patients with COVID-19. French study? The same.

In the hands of US scientists? Maybe, but they are not studying it on the full population like the Chinese scientists did, they moved the goalpost (changed the health outcome during the trial), and they used smaller (less powerful) studies.

Remdesivir? Gilead announced early promising results, and so what does NIAID do? They shut down that trial.

How about plasma convalescent therapy, where survivors donate their antibodies for other people to recover more quickly, have lower rates of serious and critical illness, lower hospitalization rates, and lower deaths? Did you know FDA recommends it for people who cannot have access to it in a clinical trial?

You won’t hear about other efficacy studies from China, and you won’t hear about the efficacy studies of hyperbaric oxygen therapy.

You won’t hear about the multicenter guidance consensus statement published recommending use of antivirals in serious pediatric cases of COVID-19.

And of course you won’t hear about the <2% hospitalization rate achieved by the preeminent Dr. David Btownstein with his high-dose vitamin regimen either, since FTC shut down his website in which he published direct interviews of patients under his care. No deaths, and the FTC shut it down.

So, we’re launching a case series study of his treatment regimen that will lead to a study submitted to a clinical journal for peer review. [Go to ipaknowledge.org now to support – see How to Donate).

In smaller, less powered US government-related studies, hydroxychloroquine seems to lose its efficacy, and the US touts the results as more definitive than the larger, more powered studies that previously did report efficacy.

Now why would the US medico-government shut down studies and reports of treatment options that reduce the rate of serious and critical illness and death? Could it be that they want a sufficiently high mortality rate to warrant continued lock-down as a justification for their vaccine?

Kinda makes you wonder, doesn’t it. The US medico-government is willing to allow people nursing homes to die with zero – ZERO intervention – not even a glass of orange juice for the Vitamin C – no compassionate use of hydroxychloroquine + Zpak, no attempts at remdesivir, no attempts at plasma convalescent therapy, no universal open-label retrospective study like are applied to vaccines all the time, well, they are simply allowing nursing home staff members to join them in an outright passive, but nonetheless willfull, massacre.

Most of the practicing and licensed physicians I know would never sit by idly and watch a patient deteriorate and do nothing, and follow up with ventilator that blows out their patients’ lung tissues after the virus has weaked the alveoli to the periphery. They would join me the condemnation of the ongoing willful massacre of our elderly in nursing homes around the country.

Wake up, America. Here is the list of studies and web resources the medico-fascists hell bent on a COVID-19 vaccine don’t want you to know about.

On March 28, the FDA issued an emergency use authorization allowing healthcare providers to make available chloroquine phosphate or hydroxychloroquine sulfate to “patients for whom a clinical trial is not available, or participation is not feasible,” adding “FDA encourages the conduct and participation in randomized controlled clinical trials that may produce evidence concerning the effectiveness of these products in treating COVID-19.”

So where are the treatments for the elderly?

My advice to people? Keep mom and dad, grandma and grandpa the hell away from nursing homes. If they are already there, get a lawyer and demand they be tested, and if negative for active infection, get them out. If they are already infected, send the lawyer this article and have them issue a letter of a threat of a lawsuit for wrongful death and malpractice for the attending physician.

And start clamoring for criminal negligence against the Board of Directors of the nursing home. Our loved ones need not die so Fauci and Gates can have his moment in the sun with a vaccine next year.

Do you have other studies that support the use of these or other treatments to add? Drop them in the comments, with a link.

References

Hyperbaric Oxygen Therapy

[1] Thibodeax, K et al. 2020. Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series. J Wound Care 2020 May 1;29(Sup5a):S4-S8. doi: 10.12968/jowc.2020.29.Sup5a.S4. https://www.ncbi.nlm.nih.gov/pubmed/32412891

Highlight: “All the patients recovered without the need for mechanical ventilation. Following HBOT, oxygen saturation increased, tachypnoea resolved and inflammatory markers fell.”

Remdesivir

[2] Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19 — Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of Remdesivir — https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19

Highlight: “The study demonstrated that patients receiving a 10-day treatment course of remdesivir achieved similar improvement in clinical status compared with those taking a 5-day treatment course (Odds Ratio: 0.75 [95% CI 0.51 – 1.12] on Day 14). No new safety signals were identified with remdesivir across either treatment group.”

Patients: Severe manifestations of COVID-19 disease. Inclusion criteria was pneumonia and reduced oxygen levels that did not require mechanical ventilation at the time of study. Overall mortality rate 7%.

[3] NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 | NIH: National Institute of Allergy and Infectious Diseases

http://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19

Highlight: “Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo.”

[4] Inside the NIH’s controversial decision to stop its big remdesivir study https://www.statnews.com/2020/05/11/inside-the-nihs-controversial-decision-to-stop-its-big-remdesivir-study/

[5] Compassionate Use Example, Colorado, USA (Remdesivir)
Firstenberg, 2020. Successful COVID-19 rescue therapy by extra-corporeal membrane oxygenation (ECMO) for respiratory failure: a case report Patient Saf Surg 2020 May 8 14:20 https://www.ncbi.nlm.nih.gov/pubmed/32395179

Combined Treatment Effective

Triple-drug combo of anti-malaria pill hydroxychloroquine, azithromycin and ZINC improved coronavirus patients’ chances of being discharged and cut death risk by almost 50%, study finds

Highlight: “Results showed that patients receiving the triple-drug combination had a 1.5 times greater likelihood of recovering enough to be discharged.”

Highlight: “…an increased frequency of being discharged home (OR 1.53, 95% CI 1.12-2.09) reduction in mortality or transfer to hospice (was) significant (OR 0.449, 95% CI 0.271-0.744)”

Study link: https://www.medrxiv.org/content/10.1101/2020.05.02.20080036v1

https://www.dailymail.co.uk/health/article-8309337/Zinc-hydroxychloroquine-effective-COVID-19-patients-study.html

Hydroxychloroquine Phosphate

[6] Gautret et al., linical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.Travel Med Infect Disease 2020 Mar-Apr 24: 101663: doi: 10.1016/j.tmaid.2020.101663. Epub 2020 Apr 11. https://www.ncbi.nlm.nih.gov/pubmed/32289548

Highlight: “All patients improved clinically except one 86 year-old patient who died, and one 74 year-old patient still in intensive care. A rapid fall of nasopharyngeal viral load was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% of patients at Day5. Consequently patients were able to be rapidly discharged from IDU with a mean length of stay of five days.”

[7] Chen et al., 2020. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial MedRxiv https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3

[8] Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.. Intl J Antimicrobial Agents Online March 20, 2020, 105949 https://www.sciencedirect.com/science/article/pii/S0924857920300996

Plasma Convalascent Therapy

[9] Joyner et al., 2020. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients MedRxiv Preprint https://www.medrxiv.org/content/10.1101/2020.05.12.20099879v1.full.pdf

[10] US FDA, May 1, 2020. Recommendations for Investigational COVID-19 Convalescent Plasma https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma

Consensus Statements

[11] Chiotos et al., 2020. Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2. J Pediatric Infect Dis Soc 2020 Apr 22 : piaa045. Published online 2020 Apr 22. doi: 10.1093/jpids/piaa045 PMCID: PMC7188128 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188128/

Highlight: “Supportive care may be appropriate for children who are severely ill with coronavirus disease 2019. Use of potentially active antivirals should be considered, preferably as part of a clinical trial if available”

Boosting Immunity, Interferon

[12] Shen, K. 2020. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World J. Pediatric Feb 7 doi: 10.1007/s12519-020-00343-7. https://link.springer.com/content/pdf/10.1007/s12519-020-00343-7.pdf

Clinical Trials Reporting

[13] Where’s the data? In a pandemic, now is no time to sit on Covid-19 trial results https://www.statnews.com/2020/05/13/wheres-the-data-in-a-pandemic-now-is-no-time-to-sit-on-covid-19-trial-results/

Original article can be viewed here

Share Far and Wide

You must be logged in to post a comment Login